American University of Integrative Sciences

Novo Integrated Sciences Reports Fiscal Year 2023 Second Quarter Financial Results

Retrieved on:

Friday, May 26, 2023

Alternative Medicine, Health, Telemedicine, Virtual Medicine, Other Health, Managed Care, Biotechnology, Iodine, American University of Integrative Sciences, Tourbillon, Monaco, Depreciation, Growth, Environment, Security (finance), Cryptocurrency

Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the “Company” or “Novo”), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints for services and product innovation, today reported its financial results for the fiscal quarter ended February 28, 2023.

Key Points:

Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the “Company” or “Novo”), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints for services and product innovation, today reported its financial results for the fiscal quarter ended February 28, 2023.
Robert Mattacchione, Novo’s CEO and Board Chairman, stated, “During the fiscal year 2023 second quarter period, the Company paid a total of $9,086,050 to certain note holders upon conversion of their notes.
Acenzia’s and Terragenx’s revenue for the three months ended February 28, 2023 was $458,920 and $32,167, respectively.
Net loss attributed to Novo Integrated Sciences, Inc. for the three months ended February 28, 2023 was $4,621,355, representing a decrease of $183,812, or 4%, from $4,805,167 for the same period in 2022.

Novo Integrated Sciences Reports Fiscal Year 2023 First Quarter Financial Results

Retrieved on:

Wednesday, May 24, 2023

Alternative Medicine, Health, Telemedicine, Virtual Medicine, Other Health, Managed Care, Biotechnology, Exercise, American University of Integrative Sciences, Investment, COVID-19, Sale, CVI, Pharmaceutical industry, Security (finance)

Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the “Company” or “Novo”), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints for services and product innovation, today reported its financial results for the fiscal quarter ended November 30, 2022.

Key Points:

Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the “Company” or “Novo”), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints for services and product innovation, today reported its financial results for the fiscal quarter ended November 30, 2022.
Revenues for the three months ended November 30, 2022 were $3,419,280, representing an increase of $257,353, or 8.1%, from $3,161,927 for the same period in 2021.
The increase in revenue is principally due to an increase in outsourced product sales which resulted in an increase in revenue of $607,589.
Net loss attributed to Novo Integrated Sciences, Inc. for the three months ended November 30, 2022 was $3,935,413, representing an increase of $2,128,826, or 117.8%, from $1,806,587 for the same period in 2021.

Novo Integrated Sciences Signs Agreements for an Unsecured, Non-dilutive Debt Instrument with a Principal Sum of $70,000,000

Retrieved on:

Thursday, April 27, 2023

Biotechnology, Pharmaceutical, Managed Care, General Health, Health, Hospitals, Health Insurance, Clinical Trials, Monaco, American University of Integrative Sciences, Growth, Note, Procurement, Security (finance), Bank

Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today announced the issuance of an unsecured 15-year $70,000,000 promissory note with RC Consulting LLC in favor of SCP Tourbillion Monaco (the “Buyer”), for a lump sum debt funding of $57,000,000.

Key Points:

Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today announced the issuance of an unsecured 15-year $70,000,000 promissory note with RC Consulting LLC in favor of SCP Tourbillion Monaco (the “Buyer”), for a lump sum debt funding of $57,000,000.
The note provides for a yield (non-compounding) of 1.52% (zero coupon) per annum and a maturity date 15 years from the date of issuance.
The Note is unsecured and there is no provision for the conversion of debt, issuance of any class of shares, or the grant of any warrants by the Company to the Buyer.
The non-dilutive and progressively structured facility will also allow the Company the time required to properly commercialize many of its unique assets.

Novo Integrated Sciences Reports Fiscal Full Year 2022 Financial Results

Retrieved on:

Monday, April 3, 2023

Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the “Company” or “Novo”), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints providing services and product innovation, today reported its financial results for the fiscal year ended August 31, 2022.

Key Points:

Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the “Company” or “Novo”), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints providing services and product innovation, today reported its financial results for the fiscal year ended August 31, 2022.
Revenues for the year ended August 31, 2022 were $11,737,937, representing an increase of $2,432,682, or 26%, from $9,305,255 for the same period in 2021.
Net loss attributed to Novo Integrated Sciences for the year ended August 31, 2022 was $32,849,215, representing an increase of $28,387,068, or 636%, from $4,462,147 for the same period in 2021.
Subsequent to the end of fiscal year 2022, the second of two $1.875m notes was paid in full.

Novo Integrated Sciences Provides Update on Certain Current Actions and Events

Retrieved on:

Friday, March 24, 2023

Health Technology, Health, Telemedicine, Virtual Medicine, American University of Integrative Sciences, Form 10-K, Rule, Financial assistance (share purchase), Investment, Central District, SWAG, District court, Novo, CVI, Court, Security (finance), Rare-earth element

Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today provides an update with respect to certain actions and events, as follows:

Key Points:

Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today provides an update with respect to certain actions and events, as follows:
As previously reported, on December 23, 2022, Novo entered into a Share Purchase Agreement (the “SWAG Agreement”) with SwagCheck Inc. (“SWAG”) and the shareholders of SWAG, pursuant to which Novo agreed to purchase 100% of SWAG’s outstanding shares.
Pursuant to the terms of the SWAG Agreement, as amended, the SWAG Agreement was to close no later than January 10, 2023.
Although the SWAG Agreement has not yet closed, the parties continue to work together with the intention of closing the transaction.
Between February 13, 2023 and March 23, 2023 the Company issued 4,100,687 shares of common stock to certain note holders upon conversion of their notes.

Announcing the Dr. Monti Show on Integrative Health and the Intersection of Science, Health, and Personal Well-Being, Premiering March 24, 2023, at 7:30pm

Retrieved on:

Tuesday, March 21, 2023

Tapestry, Alternative medicine, Education, Thomas Jefferson University, Quality of life, Medicine, Thomas Jefferson University Hospital, MBA, Brain, American University of Integrative Sciences, Thought, MD, Patient, Physician, Risk, Medical device, Health

PHILADELPHIA, March 21, 2023 /PRNewswire/ -- Daniel A. Monti, MD is excited to announce the launch of his new series, The Dr. Monti Show, where complex, holistic health topics will be presented in an accessible and engaging manner to educate and empower audiences. The Dr. Monti Show premieres March 24, 2023, at 7:30pm EST. Learn more about how to watch The Dr. Monti Show premiere on Dr. Monti's website.

Key Points:

Daniel A. Monti, MD, MBA, announces the premiere episode of a new series, The Dr. Monti Show, that will explore ground-breaking topics in integrative medicine.
Learn more about how to watch The Dr. Monti Show premiere on Dr. Monti's website.
"We explore what is possible using cutting-edge tools to assess the brain and its connection with the body," says Dr. Monti.
"My career has been dedicated to improving patient lives through the implementation of evidence-based, personalized techniques," says Dr. Monti.

Novo Integrated Sciences Announces Receipt of Notice from Nasdaq

Retrieved on:

Monday, January 30, 2023

Telecommunications, Practice Management, Finance, Health, Health Technology, Professional Services, Technology, Fitness & Nutrition, Form 10-K, American University of Integrative Sciences, Form, Annual report, Failure, Calendar, Cryptocurrency

The Company previously disclosed that it received a notice from Nasdaq on December 15, 2022 advising the Company that it was not in compliance with Rule 5250(c)(1) as a result of its failure to timely file the Form 10-K.

Key Points:

The Company previously disclosed that it received a notice from Nasdaq on December 15, 2022 advising the Company that it was not in compliance with Rule 5250(c)(1) as a result of its failure to timely file the Form 10-K.
Under Nasdaq rules, the Company has 60 calendar days from receipt of Nasdaq’s December 2022 notice, or until February 13, 2023, to submit a plan to regain compliance with Rule 5250(c)(1).
If Nasdaq accepts the Company’s plan, then Nasdaq may grant an exception of up to 180 calendar days from the due date of the Form 10-K, or until June 12, 2023, to regain compliance.
The Company intends to file the Form 10-K and the Form 10-Q as promptly as possible in order to regain compliance with Rule 5250(c)(1).

Novo Integrated Sciences’ Subsidiary, Clinical Consultants International, Signs Consulting Agreement with Pharmaceutical Research & Development Company, Sarfez Pharmaceuticals, Inc.

Retrieved on:

Wednesday, November 30, 2022

Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the Company or Novo), and Clinical Consultants International LLC (CCI), a Novo wholly-owned subsidiary, today announced the signing of a Consulting Agreement (the Agreement) with Sarfez Pharmaceuticals, Inc. (Sarfez), a pharmaceutical research and development company with an FDA-approved edema treatment for patients with heart failure and renal disease.

Key Points:

Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the Company or Novo), and Clinical Consultants International LLC (CCI), a Novo wholly-owned subsidiary, today announced the signing of a Consulting Agreement (the Agreement) with Sarfez Pharmaceuticals, Inc. (Sarfez), a pharmaceutical research and development company with an FDA-approved edema treatment for patients with heart failure and renal disease.
CCI, a Novo wholly owned subsidiary, was established in 2006 in Michigan as a local hospital consulting firm.
Headquartered in Boca Raton, Florida, CCI leverages 30+ years of industry experience and its expert consultants worldwide to support clients.
Innovation through science combined with the integration of sophisticated, secure technology assures Novo Integrated Sciences of continued cutting-edge advancement in patient-first platforms.

Novo Integrated Sciences’ Subsidiary, Clinical Consultants International, Signs Sales & Consulting Agreement with Smart Healthcare Solution Provider, TiaTech USA Inc.

Retrieved on:

Tuesday, November 8, 2022

Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the Company or Novo), and Clinical Consultants International (CCI), a Novo wholly-owned subsidiary, today announced the signing of a Sales and Consulting Agreement (the Agreement), which includes revenue-sharing potential, with TiaTech USA Inc. (TiaTech), a leader in state-of-the-art health tech solutions.

Key Points:

Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the Company or Novo), and Clinical Consultants International (CCI), a Novo wholly-owned subsidiary, today announced the signing of a Sales and Consulting Agreement (the Agreement), which includes revenue-sharing potential, with TiaTech USA Inc. (TiaTech), a leader in state-of-the-art health tech solutions.
Dr. Joseph M. Chalil, MD, MBA, FACHE, Chief Medical Officer of Novo, stated, TiaTechs ecosystem is the wave of the future for healthcare interconnectivity globally.
The TiaTech ecosystem is ideal for rural hospitals, nursing homes, assisted living, and homes where physician and specialty oversight is lacking.
Innovation through science combined with the integration of sophisticated, secure technology assures Novo Integrated Sciences of continued cutting-edge advancement in patient-first platforms.

Novo Integrated Sciences’ Subsidiary, Clinical Consultants International, Signs Sales & Consulting Agreement with Tranquility Lifestyle Solutions

Retrieved on:

Tuesday, October 25, 2022

Software, Mobile, Wireless, Data Management, IOT (Internet of Things), Consumer, Mental Health, Apps, Applications, Technology, Artificial Intelligence, Health Technology, Seniors, Health, Pillar, Orangi Pilot Project, United States Secretary of Labor, Science, Machine learning, Strategic planning, NASDAQ, Securities Act of 1933, Business Consulting International, App Store (iOS/iPadOS), Vital signs, Solution, Communication, Touchless knockout, Technology, Population, Acceleration, DSP, American University of Integrative Sciences, MBA, Clinical, Falls, Roc, Senior, Company, Industry, Consultant, Health, Health policy, Security (finance), IOT, Digital signal processor, Collection, MCU, Securities Exchange Act of 1934, U.S. Securities and Exchange Commission, CCI, Algorithm, Tranquillity, Drug Quality and Security Act, TKS, Patient, Digital signal, TLS, MD, Safety, Radar, Pharmaceutical industry, Medical imaging, Healthcare

To date, CCIs successful collaboration with Tranquility has already resulted in the launch of two separate pilot projects with a U.S.-based Senior Housing Network and a U.S.

Key Points:

To date, CCIs successful collaboration with Tranquility has already resulted in the launch of two separate pilot projects with a U.S.-based Senior Housing Network and a U.S.
These components include an integrated Digital Signal Processor (DSP) and an MCU for complex signal and image processing.
Headquartered in Boca Raton, Florida, we leverage 30+ years of industry experience and our expert consultants worldwide to support our clients.
Innovation through science combined with the integration of sophisticated, secure technology assures Novo Integrated Sciences of continued cutting-edge advancement in patient first platforms.